Investigating the "steric gate" of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by targeted insertion of unnatural amino acids.
To investigate how structural changes in the amino acid side chain affect nucleotide substrate selection in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), a variety of non-natural tyrosine analogues were substituted for Tyr115 of p66 RT. RT variants containing meta-Tyr, nor-Tyr, aminomethyl-Phe, and 1- and 2-naphthyl-Tyr were produced in an Escherichia coli coupled transcription/translation system. Mutant p66 subunits were reconstituted with wild-type (WT) p51 RT and purified by affinity chromatography. Each modified enzyme retained DNA polymerase activity following this procedure. Aminomethyl-Phe115 RT incorporated dCTP more efficiently than the WT and was resistant to the chain terminator (-)-beta-2',3'-dideoxy-3'-thiacytidine triphosphate (3TCTP) when examined in a steady-state fidelity assay. However, 2-naphthyl-Tyr115 RT inefficiently incorporated dCTP at low concentrations and was kinetically slower with all dCTP analogues tested. Models of RT containing these side chains suggest that the aminomethyl-Phe115 substitution provides new hydrogen bonds through the minor groove to the incoming dNTP and the template residue of the terminal base pair. These hydrogen bonds likely contribute to the increased efficiency of dCTP incorporation. In contrast, models of HIV-1 RT containing 2-naphthyl-Tyr115 reveal significant steric clashes with Pro157 of the p66 palm subdomain, necessitating rearrangement of the active site.
Klarmann
George J
GJ
HIV Drug Resistance Program, National Cancer Institute-Frederick, Frederick, Maryland 21702, USA.
Eisenhauer
Brian M
BM
Zhang
Yi
Y
Gotte
Matthias
M
Pata
Janice D
JD
Chatterjee
Deb K
DK
Hecht
Sidney M
SM
Le Grice
Stuart F J
SF
D019943:Amino Acid Substitution; D001665:Binding Sites; D002474:Cell-Free System; D003570:Cytidine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D003845:Deoxycytosine Nucleotides / Q000378:metabolism; D054306:Dideoxynucleotides; D004926:Escherichia coli; D054303:HIV Reverse Transcriptase / Q000737:chemistry* / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology*; D006860:Hydrogen Bonding; D007700:Kinetics; D019259:Lamivudine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D008958:Models, Molecular; D014176:Protein Biosynthesis; D015202:Protein Engineering; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism / Q000494:pharmacology; D014158:Transcription, Genetic; D014443:Tyrosine / Q000031:analogs & derivatives
D003845:Deoxycytosine Nucleotides; D054306:Dideoxynucleotides; D018894:Reverse Transcriptase Inhibitors; C417268:lamivudine triphosphate; C024107:2'-deoxycytidine 5'-triphosphate; D019259:Lamivudine; D014443:Tyrosine; D003570:Cytidine Triphosphate; D004247:DNA; D054303:HIV Reverse Transcriptase